{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:48:39Z","timestamp":1773323319039,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373250"],"award-info":[{"award-number":["82373250"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20739"],"award-info":[{"award-number":["U24A20739"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["22XD1402000"],"award-info":[{"award-number":["22XD1402000"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ygyno.2025.10.023","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:58:36Z","timestamp":1761749916000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study"],"prefix":"10.1016","volume":"203","author":[{"given":"Yizhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.10.023_bb0005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian Cancer care and unmet treatment needs for patients with platinum resistance: a narrative review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107722","article-title":"Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets","volume":"220","author":"Nameki","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0030","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1158\/1078-0432.CCR-16-1501","article-title":"Active estrogen receptor-alpha signaling in ovarian Cancer models and clinical specimens","volume":"23","author":"Andersen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ygyno.2008.03.014","article-title":"Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum","volume":"110","author":"Ramirez","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","article-title":"PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent\/metastatic low-grade ovarian cancers and serous borderline ovarian tumors","volume":"154","author":"Tang","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0035","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e86","article-title":"PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression","volume":"30","author":"Kok","year":"2019","journal-title":"J. Gynecol. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2025.10.023_bb0040","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: past, present, and future","volume":"27","author":"Monk","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24031973","article-title":"Predicting prognosis and platinum resistance in ovarian Cancer: role of immunohistochemistry biomarkers","volume":"24","author":"Atallah","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0050","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.10.023_bb0055","article-title":"Angiogenesis inhibitors for the treatment of epithelial ovarian cancer","author":"Gaitskell","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2021.08.005","article-title":"Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial","volume":"163","author":"Cowan","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2015.04.009","article-title":"A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California phase II consortia","volume":"138","author":"Hirte","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0070","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1136\/ijgc-2023-004777","article-title":"Anlotinib in patients with recurrent platinum resistant\/refractory ovarian cancer: a prospective, single arm, phase II study","volume":"33","author":"Shen","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.10.023_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24097983","article-title":"The role of the estrogen-related receptor alpha (ERRa) in hypoxia and its implications for Cancer metabolism","volume":"24","author":"Chaltel-Lima","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrc3920","article-title":"Mechanisms of aromatase inhibitor resistance","volume":"15","author":"Ma","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2025.10.023_bb0085","series-title":"Guidelines Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, version 1.2024","author":"National Comprehensive Cancer Network (NCCN)","year":"2025"},{"key":"10.1016\/j.ygyno.2025.10.023_bb0090","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0095","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1002\/ijc.33161","article-title":"A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer","volume":"147","author":"Wu","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.10.023_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102240","article-title":"Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial","volume":"64","author":"Xu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ygyno.2025.10.023_bb0105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s12916-023-03140-x","article-title":"Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial","volume":"21","author":"Fang","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0110","first-page":"21","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological Cancer intergroup (GCIG). International journal of gynecologic","author":"Rustin","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.10.023_bb0120","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/13543784.2021.1939305","article-title":"Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies","volume":"30","author":"Leung","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ygyno.2025.10.023_bb0125","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/1078-0432.CCR-06-2878","article-title":"Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients","volume":"13","author":"Smyth","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13058-020-01258-x","article-title":"TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2\/3 hormone receptor-positive and HER2-negative breast cancer","volume":"22","author":"Vaklavas","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0135","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1200\/JCO.2015.66.1595","article-title":"Phase III trial evaluating Letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast Cancer: CALGB 40503 (Alliance)","volume":"34","author":"Dickler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.drup.2011.02.004","article-title":"Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review","volume":"14","author":"Murphy","year":"2011","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0145","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.tranon.2019.02.014","article-title":"Chemotherapy modulates endocrine therapy-related resistance mutations in metastatic breast Cancer","volume":"12","author":"Zhou","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0150","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/rmb2.12402","article-title":"Differential expression of estrogen receptor subtypes in ovarian high-grade serous carcinoma and clear cell carcinoma","volume":"20","author":"Osaku","year":"2021","journal-title":"Reprod. Med. Biol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/modpathol.2010.211","article-title":"Molecular clustering based on ER\u03b1 and EIG121 predicts survival in high-grade serous carcinoma of the ovary\/peritoneum","volume":"24","author":"Schlumbrecht","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914673","article-title":"Estrogens, estrogen receptors and tumor microenvironment in ovarian Cancer","volume":"24","author":"Kozie\u0142","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2025.10.023_bb0165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10565-015-9303-z","article-title":"Effects of bisphenol a and 17\u03b2-estradiol on vascular endothelial growth factor a and its receptor expression in the non-cancer and cancer ovarian cell lines","volume":"31","author":"Ptak","year":"2015","journal-title":"Cell Biol. Toxicol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:43:03Z","timestamp":1773265383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825010479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"alternative-id":["S0090825825010479"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}